Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors

Current Opinion in Investigational Drugs

Volumn 9, Issue 6, 2008, Pages 614-630

  McCubrey, J A ^a   Milella, M ^b   Tafuri, A ^c   Martelli, A M ^d   Lunghi, P ^e   Bonati, A ^e,f   Cervello, M ^g   Lee, J T ^a,h   Steelman, L S ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g CNR   (Italy)

^h WISTAR INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer; ERK; Inhibitor; MEK; Raf; Signal transduction

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 7 HYDROXYSTAUROSPORINE; A 443654; A RAF KINASE; AAL 881; ANTINEOPLASTIC AGENT; AP 23573; B RAF KINASE; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; IMATINIB; L 779450; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; OSU 03012; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLX 4032; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PX 866; RAF 265; RAF PROTEIN; RAF PROTEIN INHIBITOR; RAS PROTEIN; SMALL MOLECULE INHIBITOR; SORAFENIB; TEMSIROLIMUS; UNINDEXED DRUG; XL 281;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; AMINO ACID SUBSTITUTION; APOPTOSIS; BILE DUCT CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GENE MUTATION; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW; SQUAMOUS CELL CARCINOMA; THYROID CANCER; UTERINE TUBE CARCINOMA; UVEA TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE KINASES; RAF KINASES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 44649089666     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (191)

1. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P et al: Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia (2008) 22(4): 686-707. • A review of multiple aspects of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways, with an emphasis on leukemia.
2. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P et al: Targeting survival cascades induced by activation of Raf/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia (2008) 22(4):708-722. • A review on the prospects of targeting the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and JAK/STAT pathways, with an emphasis on leukemia.
3. Lee JT Jr, McCubrey JA: Targeting the Raf kinase cascade in cancer therapy - novel molecular targets and therapeutic strategies. Expert Opin Ther Targets (2002) 6(6):659-678.
4. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochem Biophys Acta (2007) 1773(8):1263-1284.
5. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV, Cheng JQ: AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci (2005) 10:975-987.
6. Matsuguchi T, Salgia R, Hallek M, Eder M, Druker B, Ernst TJ, Griffin JD: Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem (1994) 269(7):5016- 5021.
7. Inhorn RC, Carlesso N, Durstin M, Frank DA, Griffin JD: Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor β-chain involving tyrosine-750. Proc Natl Acad Sci USA (1995) 92(19):8665-8669.
8. Okuda K, Foster R, Griffin JD: Signaling domains of the β c chain of the GM-CSF/IL-3/IL-5 receptor. Ann NY Acad Sci (1999) 872:305-313.
9. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE: Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med (1994) 179(1):167-175.
10. Lanfrancone L, Pelicci G, Brizzi MF, Aronica MG, Casciari C, Giuli S, Pegoraro L, Pawson T, Pelicci PG, Arouica MG: Overexpression of Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/Sos and Grb2/p140 complexes to the β receptor subunit. Oncogene (1995) 10(5):907-917.
11. Minden A, Lin A, McMahon M, Lange-Carter C, Dérijard B, Davis RJ, Johnson GL, Karin M: Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science (1994) 266(5191):1719-1723.
12. Lange-Carter CA, Johnson GL: Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science (1994) 265(5177):1458-1461.
13. Marais R, Light Y, Paterson HF, Marshall CJ: Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J (1995) 14(13):3136-3145.
14. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ: Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem (1997) 272(7):4378-4383.
15. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R: Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J (1999) 18(8):2137-2148.
16. Xu S, Robbins D, Frost J, Dang A, Lange-Carter C, Cobb MH: MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA (1995) 92(15):6808- 6812.
17. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science (1998) 282(5392):1318-1321.
18. 125 by ERK MAPK. Nature Cell Biol (2003) 5(7):647-654.
19. Dérijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ: Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. Science (1995) 267(5198):682-685.
20. Xing J, Ginty DD, Greenberg ME: Coupling of the Ras-MAPK pathway to gene activation by Rsk2, a growth factor regulated CREB kinase. Science (1996) 273(5277):959-963.
21. Coutant A, Rescan C, Gilot D, Loyer P, Guguen-Guillouzo C, Baffet G: PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival. Hepatology (2002) 36(5):1079-1088.
22. Iijima Y, Laser M, Shiraishi H, Willey CD, Sundaravadivel B, Xu L, McDermott PJ, Kuppuswamy D: c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem (2002) 277(25):23065-23075.
23. Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA, Mirza A, McMahon M, White MK, McCubrey JA: Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: Identification of an Achilles heel in leukemia. Leukemia (2003) 17(6):1058-1067.
24. Deng T, Karin M: c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature (1994) 371(6493):171-175.
25. Davis RJ: Transcriptional regulation by MAP kinases. Mol Reprod Dev (1995) 42(4):459-467.
26. Robinson MJ, Stippec SA, Goldsmith E, White MA, Cobb MH: A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol (1998) 8(21):1141-1150.
27. Aplin AE, Stewart SA, Assoian RK, Juliano RL: Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol (2001) 153(2):273-282.
28. McCubrey JA, May WS, Duronio V, Mufson A: Serine/threonine phosphorylation in cytokine signal transduction. Leukemia (2000) 14(1):9-21.
29. Tresini M, Lorenzini A, Frisoni L, Allen RG, Cristofalo VJ: Lack of Elk-1 phosphorylation and dysregulation of the extracellular regulated kinase signaling pathway in senescent human fibroblast. Exp Cell Res (2001) 269(2):287-300.
30. Eblen ST, Catling AD, Assanah MC, Weber MJ: Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2. Mol Cell Biol (2001) 21(1):249-259.
31. Adachi T, Kar S, Wang M, Carr BI: Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J Cell Physiol (2002) 192(2):151-159.
32. Wang CY, Bassuk AG, Boise LH, Thompson CB, Bravo R, Leiden JM: Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors. Mol Cell Biol (1994) 14(2):1153-1159.
33. Thomas RS, Tymms MJ, McKinlay LH, Shannon MF, Seth A, Kola I: ETS1, NFκB and AP1 synergistically transactivate the human GM-CSF promoter. Oncogene (1997) 14(23):2845-2855.
34. Ponti C, Gibellini D, Boin F, Melloni E, Manzoli FA, Cocco L, Zauli G, Vitale M: Role of CREB transcription factor in c-fos activation in natural killer cells. Eur J Immunol (2002) 32(12):3358-3365.
35. Fry TJ, Mackall CL: Interleukin-7: From bench to clinic. Blood (2002) 99(11):3892-3904.
36. Deng X, Kornblau SM, Ruvolo PP, May WS Jr: Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr (2001) 28:30-37.
37. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M: Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia (2003) 17(11):2081-2089.
38. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, Grant S: Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood (2003) 102(5):1824-1832.
39. Troppmair J, Rapp UR: Raf and the road to cell survival: A tale of bad spells, ring bearers and detours. Biochem Pharmacol (2003) 66(8):1341-1345.
40. Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ: Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA (2004) 101(43):15313-15317.
41. Marani M, Hancock D, Lopes R, Tenev T, Downward J, Lemoine NR: Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene (2004) 23(14):2431-2441.
42. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ: Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem (2003) 278(21):18811-18816.
43. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, Wagner EF, Cook SJ: Activation of ERK1/2 by δRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene (2003) 22(9):1281-1293.
44. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW: MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene (2004) 23(31):5301-5315.
45. Gëlinas C, White E: BH3-only proteins in control: Specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev (2006) 19(11):1263-1268.
46. O'Neill E, Rushworth L, Baccarini M, Kolch W: Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene Raf. Science (2004) 306(5705):2267-2270.
47. O'Neill EE, Matallanas D, Kolch W: Mammalian sterile 20-like kinases in tumor suppression: An emerging pathway. Cancer Res (2005) 65(13):5485-5487.
48. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF: The antiapoptotic gene Mcl-1 is upregulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol (1999) 19(9):6195-6206.
49. L and Bcl-2, displaces Bax and promotes cell death. Cell (1995) 80(2):285-291.
50. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE: Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem (2000) 275(15):10761-10766.
51. Pugazhenthi S, Miller E, Sable C, Young P, Heidenreich KA, Boxer LM, Reusch JE: Insulin-like growth factor-I induces Bcl-2 promoter through the transcription factor c-AMP-response element-binding protein. J Biol Chem (1999) 274(39):27529-27535.
52. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and independent mechanisms. Science (1999) 286(5443):1358- 1362.
53. Datta SR, Dudek, H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 91(2):231-241.
54. Harada H, Becknell B, Wilm M, Mann M, Huang LJ, Taylor SS, Scott JD, Korsmeyer SJ: Phosphorylation and inactivation of BAD by mitochondria- anchored protein kinase A. Mol Cell (1999) 3(4):413-422.
55. Sunayama J, Tsuruta F, Masuyama N, Gotoh Y: JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol (2005) 170(2):295-304.
56. She QB, Solit DB, Ye Q, O'Reillly KE, Lobo J, Rosen N: The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell (2005) 8(4):287-297.
57. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 17(3):393-403.
58. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ, LaMarche A, Maroney AC, Johnson EM Jr: JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron (2003) 38(6):899-914.
59. L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev (2005) 19(11):1294-1305.
60. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T: STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J (1999) 18(17):4754-4765.
61. Wang K, Gross A, Waksman G, Korsmeyer SJ: Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Mol Cell Biol (1998) 18(10):6083-6089.
62. Ernst P, Fisher JK, Avery W, Wade S, Foy D, Korsmeyer SJ: Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev Cell (2004) 6(3):437-443.
63. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff M: Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia (2004) 18(2):267-275.
64. 87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem (2006) 281(2):813-823.
65. Vrana JA, Cleaveland ES, Eastman A, Craig RW: Inducer-and cell type-specific regulation of antiapoptotic MCL-1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. Apoptosis (2006) 11(8):1275-1288.
66. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J, Umezawa A, Ichijo H: Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem (2002) 277(46):43730-43734.
67. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR: Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell (2006) 21(6):749-760.
68. Yu J, Zhang L: The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun (2005) 331(3):851-858.
69. Flotho S, Valcamonica S, Mach-Pascual G, Schmahl L, Corral J, Ritterbach H, Hasle M, Aricò M, Biondi CM: RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia (1999) 13(1):32-37.
70. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut (2003) 52(5):706-712.
71. Garnett MJ, Marais R: Guilty as charged: B-Raf is a human oncogene. Cancer Cell (2004) 6(4):313-319.
72. Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C et al: Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res (2006) 66(7):3401-3408.
73. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N et al: Mutations of the BRAF gene in human cancer. Nature (2002) 417(6892):949-954.
74. Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travali S, McCubrey JA: Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle (2006) 4(10):1382-1384.
75. Fransén K, Klintenäs M, Osterström A, Dimberg J, Monstein HJ, Söderkvist P: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis (2004) 25(4):527-533.
76. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 116(6):855-867.
77. Buscà R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychène A, Ortonne JP, Ballotti R: Ras mediates the cAMP-dependent activation of extracellular signal-regulated in melanocytes. EMBO J (2000) 19(12):2900-2910.
78. Rushworth LK, Hindley AD, O'Neill E, Kolch W: Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol (2006) 26(6):2262-2272.
79. Garnett MJ, Rana S, Paterson H, Barford D, Marais R: Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell (2005) 20(6):963-969.
80. Rajagopalan H, Bordelli A, Lengauer C, Kinzler KN, Vogelstein B, Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 418(6901):934.
81. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA et al: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res (2002) 62(22):6451-6455.
82. Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, Sebolt-Leopold J, Konopleva M, Andreeff M: Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia (2005) 19(9):1543- 1549.
83. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M: Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 108(7):2358-2365.
84. Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA: The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: What's genetics got to do with it? Expert Opin Ther Targets (2005) 9(5):1009-1030.
85. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350(21):2129-2139.
86. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 305(5687):1163-1167.
87. Sequist LV, Haber DA, Lynch TJ: Epidermal growth factor receptor mutations in non-small cell lung cancer: Predicting clinical response to kinase inhibitors. Clin Cancer Res (2005) 11(16):5668-5670.
88. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA (2004) 101(36):13306-13311.
89. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 2(1):e17.
90. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR et al: BRAF mutation predicts sensitivity to MEK inhibition. Nature (2006) 439(7074):358-362.
91. Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA: Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle (2005) 4(6):822-830.
92. McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalsan T, McMahon M: Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene (2004) 23(47):7810-7820.
93. Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA, Andreeff M: Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res (2005) 65(21):9962-9970.
94. Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H, McMahon M, McCubrey JA: A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. Oncogene (2000) 19(4):526-536.
95. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M, Cherwinski H, Bosch E, McMahon M, McCubrey JA: Differential abilities of the Raf family of protein kinases to abrogate cytokine-dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia (2000) 14(4):642-656.
96. McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, Cherwinski H, Bosch E, McMahon M: Differential abilities of activated Raf oncoproteins to abrogate cytokine-dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia (1998) 12(12):1903-1929.
97. Shelton JG, Blalock WL, White ER, Steelman LS, McCubrey JA: Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle (2004) 3(4):503-512.
98. Steelman LS, Bertrand FE, McCubrey JA: The complexity of PTEN: Mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets (2004) 8(6):537-550.
99. Navolanic PM, Steelman LS, McCubrey JA: EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol (2003) 22(2):237-252.
100. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M: Phosphatidylinositol-3-OH kinase or Ras pathway mutations in human breast cancer cell lines. Mol Cancer Res (2007) 5(2):195-201.
101. Lee JT Jr, McCubrey JA: The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia (2002) 16(4):486-507.
102. Barnes G, Bulusu VR, Hardwick RH, Carroll N, Hatcher H, Earl HM, Save VE, Balan K, Jamieson NV: A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec). Int J Surg (2005) 3(3):206-212.
103. Hochhaus A, McCubrey JA, Killmann NMB: Spotlight imatinib: A model for signal transduction inhibitors. Leukemia (2002) 16(7):1205- 1206.
104. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M: Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat (2007) 10(3):81-100.
105. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K et al: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA (2008) 105(8):3041-3046. • Key manuscript decribing the development of mutant B-Raf selective inhibitors.
106. NCT00304525: A study to evaluate RAF265, an oral drug administered to subjects with locally advanced or metastatic melanoma. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrial.gov/ct2/show/NCT00304525?term= NCT00304525&rank=1
107. Huynh H, Soo KC, Chow PKH, Tran E: Targeted inhibition of the extracellular signal-regulated kinases kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther (2007) 6(1):138-146.
108. Huynh H, Chow PK, Soo KC: AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther (2007) 6(9):2468-2476.
109. Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA, McMahon M, McCubrey JA: Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia (2003) 17(9):1765-1782.
110. Heimbrook DC, Huber HE, Stirdivant SM, Claremon D, Liverton N, Patrick DR, Selnick H, Ahern J, Conroy R, Drakas R, Falconi N et al: Identification of potent, selective kinase inhibitors of Raf. Proc Am Assoc Cancer Res (1998) 39: Abs 3793.
111. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P: Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 6(8):559-568.
112. Lyons JF, Wilhelm S, Hibner B, Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer (2001) 8(3):219-225.
113. Delaney AM, Printen JA, Chen H, Fauman EB, Dudley DT: Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol Cell Biol (2002) 22(21):7593- 7602.
114. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 351(1):95-105.
115. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT et al: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol (2004) 11(12):1192-1197.
116. Tai YT, Li XF, Breitkreutz I, Song W, Burger P, Rumizen M, Hideshima T, Podar K, Ghobrial I, Schlossman R, Richardson P et al: Inhibition of ERK1/2 activity by the MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma cell apoptosis in the bone marrow microenvironment: A new therapeutic strategy for MM. Blood (2006) 108: Abs 3463.
117. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, et al: Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 13(5):1576-1583.
118. Wang D, Boerner SA, Winkler JD, LoRusso PM: Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007 1773(8):1248-1255.
119. Mazzucchelli C, Vantaggiato C, Ciamei A, Fasano S, Pakhotin P, Krezel W, Welzl H, Wolfer DP, Pagès G, Valverde O, Marowsky A et al: Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron (2002) 34(5):807-820.
120. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 64(19):7099-7109. • Key initial manuscript describing the effects of sorafenib.
121. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP: Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 65(6):2412-2421.
122. Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, Dong C, Robertson GP: Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res (2006) 66(16):8200-8209.
123. Nagy A, Balint I, Kovacs G: Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. Int J Cancer (2003) 106(6):980-981.
124. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R: B-RAF is a therapeutic target in melanoma. Oncogene (2004) 23(37):6292-6298. • This is a key paper documenting the importance of B-Raf mutations in cancer growth.
125. Poulikakos PI, Joseph EW, Tsai J, Bollag G, Rosen N: The RAF inhibitor PLX-4032 effectively suppresses MAPK signaling in cells harboring mutant B-raf, but not in cells with upstream activation of the pathway. Am Assoc Canc Res Annual Meeting (2008) 99:Abs 5800.
126. Tsai J, Zhang J, Bremer R, Artis R, Hirth P, Bollag G: Development of a novel inhibitor of oncogenic B-Raf. Am Assoc Canc Res Annual Meeting (2006) 47:Abs 2412.
127. V600E tumor proliferation and MAPK signaling in vitro and in vivo. Am Assoc Canc Res Annual Meeting (2008) 99:Abs 3437.
128. NCT00405587: Safety study of PLX-4032 in patients with solid tumors. NIH, Bethesda, MD, USA (2006). http://clinicaltrials.gov/ct2/ show/NCT00405587?term=NCT00405587&rank=1.
129. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH: CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Cancer (2005) 104(5):1045-1048.
130. Molhoek KR, Brautigan DL, Slingluff CL Jr: Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Transl Med (2005) 3:39. • Key paper documenting potential for combined signal transduction inhibitor therapy.
131. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A et al: Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 13(5):1576-1583. • Key manuscript documenting novel MEK inhibitors.
132. NCI: SEER stat fact sheets - Cancer of the pancreas. World Wide Web Site (2008):April 29. http://seer.cancer.gov/statfacts/html/ pancreas.html
133. NCT00600496: A phase I, open-label, multi-center study to assess the safety, tolerability and pharmacokinetics of AZD6244 (ARRY-142886). NIH, Bethesda, MD, USA (2008). http://www.clinicaltrials.gov/ct2/show/NCT00600496? term=arry-142886&rank=1
134. NCT00085787: Tolerability study of investigational agent, ARRY-142886, in patients with cancer. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrial.gov/ct2/show/NCT00085787?term=NCT00085787&rank= 1
135. NCT00463814: AZD6244 (ARRY-142886) solid oral dosage formulation in patients with advanced solid malignancies. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrials.gov/ct2/show/NCT00463814?term=arry-142886&rank= 3
136. NCT00338130: Randomised study to compare the efficacy of AZD6244 vs TMZ. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrials.gov/ct2/ show/NCT00338130?term=arry-142886&rank=2
137. NCT00372944: AZD6244 vs. capecitabine (Xeloda) in patients with advanced or metastatic pancreatic cancer, who have failed first line gemcitabine therapy. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrials.gov/ ct2/show/NCT00372944?term=arry-142886&rank=5
138. NCT00372788: AZD6244 versus pemetrexed (Alimta) in patients with non-small cell lung cancer, who have failed one or two prior chemotherapy regimen. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrials.gov/ ct2/show/NCT00372788?term=arry-142886&rank=4
139. NCT00514761: Phase II efficacy study of AZD6244 in colorectal cancer. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrials.gov/ct2/ show/NCT00514761?term=arry-142886&rank=7
140. NCT00551070: AZD6244 in treating woman with recurrent low-grade ovarian cancer. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrial. gov/ct2/show/NCT00551070?term=nct00551070&rank=1
141. NCT00553332: AZD6244 in treating patients with biliary cancer that cannot be removed by surgery. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrial.gov/ct2/show/NCT00553332?term=nct00553332&rank= 1
142. NCT00588809: AZD6244 in treating patients with recurrent or refractory acute myeloid leukemia. NIH, Bethesda, MD, USA (2008). http://www. clinicaltrial.gov/ct2/show/NCT00588809?term=nct00588809&rank=1
143. NCT00550719: AZD6244 in treating patients with locally advanced or metastatic liver cancer. NIH, Bethesda, MD, USA (2008). http://www. clinicaltrial.gov/ct2/show/NCT00550719?term=nct00550719&rank=1
144. NCT00559949: AZD6244 in treating patients with papillary thyroid cancer that did not respond to radioactive iodine. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrial.gov/ct2/show/NCT00559949?term= Nct00559949&rank=1
145. NCT00604721: A phase 2 study of AZD6244 in hepatocellular carcinoma. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrial.gov/ ct2/show/NCT00604721?term=ARRY-142886&rank=6
146. Sebolt-Leopold JS, Merriman R, Omer C et al: The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential. Proc Am Assoc Cancer Res (2004) 45: Abs 4003.
147. Brown AP, Carlson TC, Loi CM, Graziano MJ: Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol (2007) 59(5):671-679.
148. Allen LF, Sebolt-Leopold J, Meyer MB: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol (2003) 30 (5 Suppl 16):105-116.
149. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 22(22):4456-4462.
150. McCubrey JA, Steelman LS, Moye PW, Hoyle PE, Weinstein-Oppenheimer C, Chang F, Pearce M, White MK, Franklin R, Blalock WL: Effects of deregulated RAF and MEK1 expression on the cytokine-dependency of hematopoietic cells. Adv Enzyme Regul (2000) 40(1):305-337. • Key manuscript documenting sensitivity of hematopoietic cells with various mutant Raf and MEK genes to MEK and other kinase inhibitors.
151. Ricciardi MR, Milella M, Scerpa MC, Gregorj C, De Cave F, Abrams S, Steelman L, Chiaretti S, Konopleva M, Petrucci MT, Cognetti F et al: Targeting the RAF/MEK/ERK signaling pathway by the novel MEK inhibitor PD0325901: Molecular and functional effects in pre-clinical leukemia models. Haematologica (2007) 92(Suppl 1): Abs 747.
152. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M: A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 21(4):379-384. • Key paper documenting the creation of a conditional B-Raf mutant mouse, which can be used to evaluate Raf and MEK inhibitors.
153. Lorusso P, Krishnamurthi S, Rinehart JR, Nabell L, Croghan G, Varterasian M, Sadis SS, Menon SS, Leopold J, Meyer MB: A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol (2005) 26(16S): Abs 3011.
154. NCT00147550: MEK inhibitor PD-325901 to treat advanced breast cancer, colon cancer, and melanoma. NIH, Bethesda, MD, USA (2008). http://www.clinicaltrial.gov/ct2/show/NCT00147550?term=NCT00147550&rank= 1
155. NCT00174369: MEK inhibitor PD-325901 to treat advanced non-small cell lung cancer. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrial.gov/ ct2/show/NCT00174369?term=NCT00174369&rank=1
156. Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L: Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia (2006) 20(6):911-928.
157. Rolfe M, McLeod LE, Pratt PF, Proud CG: Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem J (2005) 388(3):973-984.
158. Adjei AA, Mandrekar S, Marks RS, Hanson LJ, Aranguren D, Jett JR, Simantov R, Schwartz B, Croghan GA: A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). J Clin Oncol 23(16S): Abs 3067.
159. Legrier ME, Yang CPH, Yan HG, Lopez-Barcons L, Keller SM, Pérez-Soler R, Horwitz SB, McDaid HM: Targeting protein translation in human non-small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res (2007) 67(23):11300-11308. • Key manuscript documenting mechanism of action of synergy between MEK and mTOR inhibitors.
160. Abou-Alfa GK, Johnson P, Knox J, Lacava J, Leung T, Mori A, Leberre MA, Voliotis D, Saltz L: 3500 ORAL preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer Suppl (2007) 5(4):259.
161. NCT00464919: Sorafenib plus Tegafur/Uracil (UFUR® ) for HCC. NIH, Bethesda, MD, USA (2007). http://www.clinicaltrial.gov/ct2/show/ NCT00464919?term=NCT00464919&rank=1
162. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res (2002) 62(1):188-199.
163. Yu C, Dasmahapatra G, Dent P, Grant S: Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia (2005) 19(9):1579-1589.
164. Cusimano A, Foderà D, D'Alessandro N, Lampiasi N, Azzolina A, Montalto G, Cervello M: Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther (2007) 6(9):1461-1468.
165. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez-Soler R, Horwitz SB: Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res (2005) 65(7):2854-2860.
166. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K et al: Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem (2002) 277(36):33490-33500.
167. Brognard J, Dennis PA: Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ (2002) 9(9):893-904.
168. Aoki K, Ogawa T, Ito Y, Nakashima S: Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma. Oncol Rep (2004) 11(2):375-379.
169. Park SA, Park HJ, Lee BI, Ahn YH, Kim SU, Choi KS: Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol (2001) 93(1):18-26.
170. Lunghi P, Tabilio A, Lo-Coco F, Pelicci PG, Bonati A: Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia (2005) 19(2):234-244.
171. Lunghi P, Costanzo A, Salvatore L, Noguera N, Mazzera L, Tabilio A, Lo-Coco F, Levrero M, Bonati A: MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood (2006) 107(11):4549-4553.
172. Dai Y, Landowski TH, Rosen ST, Dent P, Grant S: Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood (2002) 100(9):3333-3343.
173. Rieber M, Rieber MS: Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status. Int J Cancer (2006) 118(5):1135-1143.
174. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA, Martelli AM: The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia (2007) 21(5):886-896.
175. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL: Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens (2004) 22(6):1141-1149.
176. Cavanaugh JE, Ham J, Hetman M, Poser S, Yan C, Xia Z: Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci (2001) 21(2):434-443.
177. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA: Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res (2006) 12(6):1785-1793.
178. Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O, Moore MJ: Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res (2006) 12(1):144-151.
179. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 5(7):810-816.
180. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P et al: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 23(23):5281-5293.
181. Lorusso P, Krishnamurthi S, Rinehart JR, Nabell L, Croghan G, Varterasian M, Sadis SS, Menon SS, Leopold J, Meyer MB: A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol (2005) 23(16S): Abs 3001.
182. Menon SS, Whitfield LR, Sadis S, Meyer MB, Leopold J, Lorusso PM, Krishnamurthi S, Rinehart JR, Nabell L, Croghan G: Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. J Clin Oncol (2005) 23(16S): Abs 3066.
183. FDA: FDA approves Nexavar for patients with inoperable liver cancer. Press Release (2007):November 19.
184. FDA: FDA approval for sorafenib tosylate. Press Release (2005): December 20.
185. Novartis Institutes for Biomedical Research: The pipeline of Novartis Oncology. (2008):May 01. http://www.novartisoncology.com/research- innovation/pipeline.jsp?usertrack.filter_applied=true&NovaId= 7852773789897598156#pipeline-top
186. Exelixis Inc: XL281. Company World Wide Web Site (2008): May 03. http://www.exelixis.com/pipeline_xl281.shtml
187. NCT00494182: Sorafenib plus carboplatin and paclitaxel in head and neck squamous cell cancer. NIH, Bethesda, MD, USA (2007) http://www.clinicaltrial.gov/ct2/show/NCT00494182?term= sorafenib+AND+carboplatin&rank=4
188. NCT00647426: Phase II study of sorafenib + carboplatin and docetaxel in first line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). NIH, Bethesda, MD, USA (2008). http://www.clinicaltrial.gov/ct2/show/ NCT00647426?term=sorafenib+AND+carboplatin&rank=5
189. Array BioPharma Inc: Topline results announced from a phase 2 study in advanced melonoma of investigational anti-cancer drug AZD6244 (ARRY-886). Press Release (2007): December 19.
190. Pfizer Inc: Pfizer pipeline. Company World Wide Web Site (2007): July 31. http://www.pfizer.com/pipeline
191. Exelixis Inc: XL518. Company World Wide Web Site (2008): May 03. http://www.exelixis.com/pipeline_xl518.shtml